Key statistics
On Monday, Akari Therapeutics PLC (AKTX:NAQ) closed at 3.20, -27.27% below its 52-week high of 4.40, set on Jul 26, 2024.
52-week range
Open | 3.20 |
---|---|
High | 3.20 |
Low | 3.20 |
Bid | 2.20 |
Offer | 3.90 |
Previous close | 3.22 |
Average volume | 6.35k |
---|---|
Shares outstanding | 607.23k |
Free float | 485.78k |
P/E (TTM) | -- |
Market cap | 39.11m USD |
EPS (TTM) | -2.98 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 20:30 BST.
More ▼
- Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
- Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
- Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
- Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
- Akari Therapeutics Secures $7.6 Million in Upsized Financing Round
- Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
More ▼